Figure 5. Analysis of 1-TbAd effects on enzymes and substrates known from human lysosomal storage diseases.

(A) The known relationships among substrates that define human genetic lysosomal storage diseases are indicated (53), emphasizing products that are 1-TbAd induced (green) or involved in eponymous lysosomal storage diseases (blue). (B) Human macrophages were treated with 20 μM 1-TbAd for 4 hours and subjected to RT-PCR. (C) Human M1 macrophages were treated with TbAd (20 μM) or lalistat-2 (100 μM), counted, and then lysed to fluorometrically measure turnover of P-PMHC as a quantitative measure of LAL action. P values were derived from an ordinary 1-way ANOVA with Dunnett’s multiple-comparison test. (D and E) Human macrophages were pretreated with the indicated compounds, followed by flow cytometric measurement of glycolipid (C₁₂FDG) or protein (DQ-BSA) probes. P values were determined by the Kruskal-Wallis multiple-comparison test.